19.10.2012 - Spanish Genmedica Therapeutics S.L. has raised €12m in a series B financing round led by the British investor Asclepios Bioresearch.
Genmedica develops dual action, small molecules which act against both oxidative stress and inflammation (OSIF), two processes that are emerging as critical in the pathogenesis of a wide range of diseases. It’s lead compound GMC-252 has shown in multiple type 2 diabetes animal models to act as a potent anti-diabetic, lowering glucose and lipids. „The deal with Asclepios allows us to quickly advance our clinical plans with an experienced partner and start dosing patients this year. This will allow us to generate phase 1 safety data in 2013 and preliminary efficacy data in early 2014“, stated Alec Mian, CEO of Genmedica.
In 2011, the Barcelona-based start upo raised €3m in a series A round from local investors Caxia Capital, BcnEmpren, Unifondo-Uninvest and Venture Cap.
15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.
12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.
09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.
The Development Microlute™ from Porvair Sciences is a Solid Phase Extraction (SPE) microplate which provides a wide assortment of phase chemistries and sorbent loadings in a single plate making it ideally suited for method development. more